Eureka Alert
Share

In the six years since its inception, CRISPR gene editing has experienced ups and downs, from giddy excitement over the technology’s potential to cure genetic diseases to patent disputes, ethical considerations and cancer scares. Despite recent setbacks, companies developing CRISPR therapies are forging ahead, reports an article in Chemical & Engineering News (C&EN), the weekly news magazine of the American Chemical Society.

The CRISPR process makes double-stranded breaks at particular sites in DNA, specified by a guide RNA, with an enzyme called Cas9. The cell machinery then repairs the DNA break, while a CRISPR template DNA sequence introduces edits to restore a defective gene’s function. The first clinical trials of CRISPR will take place within the next year. However, since May 2017, a few studies in mice and human cell lines have raised safety concerns over the technology, writes Assistant Editor Ryan Cross.

Last month, a pair of papers in Nature Medicine indicated that CRISPR doesn’t work in two human cell lines unless a protein called p53 is broken or missing. Because cancer cells often have defective p53, some media coverage linked CRISPR to cancer. However, representatives from companies developing the technology downplay these results because they are not

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD